Skip to main content
Larry A. Wheeler

Larry A. Wheeler, PhD

Languages spoken: English

Academic Information

Departments Adjunct -

Academic Office Information

Larry.Wheeler@hsc.utah.edu

Education History

Fellowship Harvard Medical School
Postdoctoral Research Associate
Harvard Medical School
Research Fellow
Doctoral Training Loma Linda University
PhD
Loma Linda University
MS
Undergraduate University of Redlands
BS

Selected Publications

Journal Article

  1. Vagin O, Tokhtaeva E, Garay PE, Souda P, Bassilian S, Whitelegge JP, Lewis R, Sachs G, Wheeler L, Aoki R, Fernandez-Salas E (2014). Recruitment of septin cytoskeletal proteins by botulinum toxin A protease determines its remarkable stability. J Cell Sci, 127(Pt 15), 3294-308.

Patent

  1. Burke J, Hughes P, Werhner O, Lin T, Escobar M, Huang G, Zhang KM, Wheeler LA, Donn R (2013). Sustained Release Intraocular Implants and Methods for Preventing Retinal Dysfunction. U.S. Patent No. 8,609,144. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Huang G, Jackson B, Burke J, Lin T, Hughes P, Wheeler L, Donn R (2013). Sustained Release Intraocular Implants and Methods for Treating Ocular Vasculopathies. U.S. Patent No. 8,580,292. Washington, D.C.:U.S. Patent and Trademark Office.
  3. Huang G, Jackson B, Burke J, Lin T, Hughes P, Wheeler L, Donn R (2013). Sustained Release Intraocular Implants and Methods for Treating Ocular Vasculopathies. U.S. Patent No. 8,506,986. Washington, D.C.:U.S. Patent and Trademark Office.
  4. Stern M, Schaumburg C, Siemasko K, Wheeler L (2013). Methods of Treating Ocular and Other Diseases with SYN-134R Polypeptide. U.S. Patent No. 8,491,912. Washington, D.C.:U.S. Patent and Trademark Office.
  5. Huang G, Burke J, Hughes P, Zhang KM, Lin T, Wheeler L, Donn R (2013). Sustained Release Intraocular Implants and Methods for Preventing Retinal Dysfunction. U.S. Patent No. 8,425,929. Washington, D.C.:U.S. Patent and Trademark Office.
  6. Huang G, Burke J, Hughes P, Zhang KM, Lin T, Wheeler L, Donn S (2012). Sustained release intraocular implants and methods for preventing retinal dysfunction. U.S. Patent No. 8,293,210 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  7. Burke J, Hughes P, Zhang KM, Lin T, Huang G, Jackson B, Wheeler L, Donn R (2012). Intraocular implants and methods for improving vision. U.S. Patent No. 8,293,741. Washington, D.C.:U.S. Patent and Trademark Office.
  8. Chow K, Heidelbaugh T, Gil D, Garst M, Wheeler LA (2011). Imidazole-2-Thiones. U.S. Patent No. 8,063,086 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  9. Heidelbaugh T, Chow K, Wheeler LA, Nguyen P, Gil D, Donello J, Garst M (2010). 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists. U.S. Patent No. 7,838,545 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  10. Ehring G, Adorante J, Wheeler LA, Malone T, Donello J (2010). Treating pain using selective antagonists of persistent sodium current. U.S. Patent No. 7,767,718 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  11. Chow K, Gil D, Fang W, Garst M, Wheeler L (2010). Methods and compositions for modulating alpha adrenergic receptor activity. U.S. Patent No. 7,754,768 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  12. Ehring G, Adorante J, Wheeler LA, Malone T, Whitcup S (2010). Treating neurological disorders using selective antagonists of persistent sodium current. U.S. Patent No. 7,728,034 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  13. Ehring G, Adorante J, Wheeler LA, Malone T, Whitcup S (2010). Treating neurological disorders using selective antagonists of persistent sodium current. U.S. Patent No. 7,705,055 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  14. Dolly J, Aoki KR, Garst ME, Wheeler LA (2009). Modification of Clostridial Toxins For Use As Transport Proteins. U.S. Patent No. 7,628,992 B1. Washington, D.C.:U.S. Patent and Trademark Office.
  15. Wheeler LA, Garst ME, Liang Y, Woodward DF, Krauss, Achim HP, Burk RM, Donde Y, Holoboski M, Old DW, Chen J (2009). Prostaglandin EP-4 Antagonists. U.S. Patent No. 7,612,082. Washington, D.C.:U.S. Patent and Trademark Office.
  16. Wheeler LA (2009). {2-(2-thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronaph}. U.S. Patent No. 7,569,595. Washington, D.C.:U.S. Patent and Trademark Office.
  17. Chow K, Heidelbaugh T, Gil D, Garst M, Wheeler LA, Nguyen PX, Gomez DG (2008). 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds. U.S. Patent No. 7,419,994. Washington, D.C.:U.S. Patent and Trademark Office.
  18. Heidelbaugh TM, Chow K, Nguyen PX, Gil DW, Donello JE, Garst ME, Wheeler LA (2008). 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists. U.S. Patent No. 7,399,868. Washington, D.C.:U.S. Patent and Trademark Office.
  19. Heidelbaugh TM, Chow K, Nguyen PX, Gil DW, Donello JE, Garst ME, Wheeler LA (2008). 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as .alpha..sub.2 adrenergic agonists. U.S. Patent No. 7,396,849. Washington, D.C.:U.S. Patent and Trademark Office.
  20. Chow K, Heidelbaugh T, Gil D, Garst M, Wheeler LA, Nguyen PX, Gomez DG (2008). 4-(substituted cycloalkylmethyl) imidazol-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds. U.S. Patent No. 7,345,077. Washington, D.C.:U.S. Patent and Trademark Office.
  21. Chow K, Gil DW, Fang WK, Garst ME, Wheeler LA (2008). Methods and compositions for modulating alpha adrenergic receptor activity. U.S. Patent No. 7,335,803. Washington, D.C.:U.S. Patent and Trademark Office.
  22. Chow K, Heidelbaugh TM, Gil DW, Garst ME, Wheeler LA (2008). 4-(substituted cycloalkylmethyl) imidazol-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds. U.S. Patent No. 7,323,485. Washington, D.C.:U.S. Patent and Trademark Office.
  23. Chow K, Heidelbaugh TM, Gil DW, Garst ME, Wheeler LA (2008). 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2-H)-one. U.S. Patent No. 7,358,269. Washington, D.C.:U.S. Patent and Trademark Office.
  24. Ehring GR, Adorante JS, Donello JE, Wheeler LA, Malone T (2006). Treating Pain Using Selective Antagonists of Persistent Sodium Current. U.S. Patent No. 7,125,908 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  25. Chow K, Heidelbaugh T, Gil D, Garst M, Wheeler L, Nguyen P, Gomez D (2006). 4-(Subtituted Cycloalkylmethyl) Imidazole-2-Thiones,4-(Substituted Cycloalkenylmethyl) Imidazole-2-Thiones, 4-(Substituted Cycloalkylmethyl) Imidazol-2-Ones and 4-(SubstitutedCycloalkenylmethyl)Imidazol-2-Ones and Related Compounds. U.S. Patent No. 7,091,232. Washington, D.C.:U.S. Patent and Trademark Office.
  26. Ehring GR, Adorante JS, Wheeler LA, Malone T, Whitcup SM (2005). Treating Neurological Disorders Using Selective Antagonists of Persistent Sodium Current. U.S. Patent No. 7,060,723 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  27. Chow K, Gil DW, Burke JA, Harcourt DA, Garst ME, Wheeler LA, Munk SA, Gomez DG, Heidelbaugh TM (2005). Imidiazoles having reduced side effects. U.S. Patent No. 6,841,684. Washington, D.C.:U.S. Patent and Trademark Office.
  28. Campochiaro PA, Wheeler LA, Chandraratna RA, Nagpal S, De Juan Jr E (2003). Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists. U.S. Patent No. 6,573,271. Washington, D.C.:U.S. Patent and Trademark Office.
  29. Chow K, Gil DW, Fang W, Garst ME, Wheeler LA (2003). Methods and compositions for modulating alpha adrenergic receptor activity. U.S. Patent No. 6,545,182. Washington, D.C.:U.S. Patent and Trademark Office.
  30. Wheeler LA, Woldemussie E, Lai RK (2002). Methods of using (2-imidiazolin-2-ylamino) quinoxalines in treating ocular neural injury. U.S. Patent No. 6,465,464. Washington, D.C.:U.S. Patent and Trademark Office.
  31. Campochiaro PA, Wheeler LA, Chandraratna RA, Nagpal S, De Juan Jr E (2002). Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists. U.S. Patent No. 6,372,753. Washington, D.C.:U.S. Patent and Trademark Office.
  32. Chow K, Gil DW, Burke JA, Harcourt DA, Garst ME, Wheeler LA, Munk SA (2001). Methods of treating pain and other conditions. U.S. Patent No. 6,329,369. Washington, D.C.:U.S. Patent and Trademark Office.
  33. Burke JA, Garst ME, Wheeler LA (2001). Methods for using (2-imidiazolin-2-ylamino) quinoxaline derivatives. U.S. Patent No. 6,323,204. Washington, D.C.:U.S. Patent and Trademark Office.
  34. Chow K, Gil D, Fang WK, Garst ME, Wheeler L (2001). Methods and compositions for modulating alpha adrenergic receptor activity. U.S. Patent No. 6,313,172. Washington, D.C.:U.S. Patent and Trademark Office.
  35. Wheeler LA, Woldemussie E, Lai RK (2001). Methods of using (2-imidiazolin-2-ylamino) quinoxaline in treating ocular neural injury. U.S. Patent No. 6,248,741. Washington, D.C.:U.S. Patent and Trademark Office.
  36. Dolly JO, Aoki KR, Wheeler LA, Garst ME (2001). Modification of clostridial toxins for use as transport proteins. U.S. Patent No. 6,203,794. Washington, D.C.:U.S. Patent and Trademark Office.
  37. Wheeler LA, Woldemussie E, Lai RK (2001). Methods of using (2-imidiazolin-2-ylamino) quinoxaline in treating neural injury. U.S. Patent No. 6,194,415. Washington, D.C.:U.S. Patent and Trademark Office.
  38. Campochiaro PA, Wheeler LA, Chandraratna RA, Nagpal S, De Juan Jr E (2000). Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists. U.S. Patent No. 6,075,032. Washington, D.C.:U.S. Patent and Trademark Office.
  39. Campochiaro PA, Wheeler LA, Chandraratna RA, Nagpal S (2000). Method preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists. U.S. Patent No. 6,071,924. Washington, D.C.:U.S. Patent and Trademark Office.
  40. Stern ME, Wheeler LA, Nicolson MA (1999). Use of platelet derived growth factor in ophthalmic wound healing. U.S. Patent No. 5,863,892. Washington, D.C.:U.S. Patent and Trademark Office.
  41. Wheeler LA, Woldemussie E, Lai RK (1999). Methods of using (2-imidiazolin-2-ylamino) quinoxaline in treating ocular neural injury. U.S. Patent No. 5,856,329. Washington, D.C.:U.S. Patent and Trademark Office.
  42. Campochiaro PA, Wheeler LA, Chandraratna RA, Nagpal S (1998). Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists. U.S. Patent No. 5,824,685. Washington, D.C.:U.S. Patent and Trademark Office.
  43. Burke JA, Garst ME, Wheeler LA (1998). Methods for using (2-imidiazolin-2-ylamino) quinoxaline derivatives. U.S. Patent No. 5,773,440. Washington, D.C.:U.S. Patent and Trademark Office.
  44. Burke JA, Garst ME, Wheeler LA (1998). Methods for using (2-imidiazolin-2-ylamino) quinoxaline derivatives. U.S. Patent No. 5,756,503. Washington, D.C.:U.S. Patent and Trademark Office.
  45. Aoki KR, Wheeler LA, Garst ME (1998). Injectable therapy for control of muscle spasms and pain related to muscle spasms. U.S. Patent No. 5,721,215. Washington, D.C.:U.S. Patent and Trademark Office.
  46. Burke JA, Garst ME, Wheeler LA (1998). Methods for using (2-Imidazolin-2-Ylamino) Quinoxaline derivatives. U.S. Patent No. 5,714,486. Washington, D.C.:U.S. Patent and Trademark Office.
  47. Garst ME, Burke JE, Wheeler LA (1998). Method for using pharmaceutical compositions containing 2-(2-Alkyphenyl-Amino)-Thiazolines as adrenergic agents. U.S. Patent No. 5,708,015. Washington, D.C.:U.S. Patent and Trademark Office.
  48. Burke JA, Garst ME, Wheeler LA (1997). Methods for using (2-imidiazolin-2-ylamino) quinoxaline derivatives. U.S. Patent No. 5,703,077. Washington, D.C.:U.S. Patent and Trademark Office.
  49. Garner WH, Wheeler LA (1996). Use of 2-substituted-thiazolidine-4-carboxylic acids for treatment of cataract. U.S. Patent No. 5,589,464. Washington, D.C.:U.S. Patent and Trademark Office.
  50. Burke JA, Garst ME, Wheeler LA (1996). Methods for using (2-imidiazolin-2-ylamino) quinoxaline derivatives. U.S. Patent No. 5,587,376. Washington, D.C.:U.S. Patent and Trademark Office.
  51. Garst ME, Burke JE, Wheeler LA (1996). Methods for using 2-(2-alkylphenylamino)- oxazolines as adrenergic agents. U.S. Patent No. 5,580,892. Washington, D.C.:U.S. Patent and Trademark Office.
  52. Burke JA, Garst ME, Wheeler LA (1996). Methods for using (2-imidiazolin-2-ylamino) quinoxaline derivatives. U.S. Patent No. 5,561,132. Washington, D.C.:U.S. Patent and Trademark Office.
  53. Burke JA, Garst ME, Wheeler LA (1996). Methods for using (2-imidiazolin-2-ylamino) quinoxaline derivatives. U.S. Patent No. 5,552,403. Washington, D.C.:U.S. Patent and Trademark Office.
  54. Gluchowski C, Garst ME, Burke JA, Wheeler LA (1995). Methods for using (2-imidiazolin -2-ylamino) quinoxaline derivatives. U.S. Patent No. 5,418,234. Washington, D.C.:U.S. Patent and Trademark Office.
  55. Garner WH, Wheeler LA (1995). Use of 2-substituted-thiszolidine-4-carboxylic acids for treatment of cataract. U.S. Patent No. 5,399,573. Washington, D.C.:U.S. Patent and Trademark Office.
  56. Gluchowski C, Garst ME, Burke JA, Wheeler LA (1994). Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives. U.S. Patent No. 5,373,010. Washington, D.C.:U.S. Patent and Trademark Office.
  57. Gluchowski C, Garst ME, Burke JA, Wheeler LA (1994). Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives. U.S. Patent No. 5,326,763. Washington, D.C.:U.S. Patent and Trademark Office.
  58. Muallem S, Sachs G, Wheeler LA (1989). Use of manoalide and its derivatives for modifying calcium homeostasis. U.S. Patent No. 4,839,385. Washington, D.C.:U.S. Patent and Trademark Office.
  59. Wheeler LA (1988). Treatment of cutaneous hyperproliferative dermatoses with manoalide. U.S. Patent No. 4,786,651. Washington, D.C.:U.S. Patent and Trademark Office.
  60. Wheeler L (1985). Novel ophthalmic composition for treatment of ocular allergic disease. U.S. Patent No. 4,524,063. Washington, D.C.:U.S. Patent and Trademark Office.
  61. Burke JA, Garst ME, Gluchowski C, Wheeler LA (1983). Methods for using alpha-2 agonist imidazolin quinoxaline derivatives for receiving pain, as an anaesthetic, basoconstrictor, decongestant and anti-inflammatory and for treating ischemiz. U.S. Patent No. 5,231,096. Washington, D.C.:U.S. Patent and Trademark Office.